LGND

#3926
Ligand Pharmaceuticals Incorporated - Common Stock
2.3 2 USD
-99.01%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
2.32
2.32
년간 변동
2.29
247.38
일일 변동
-99.01%
월간 변동
-98.97%
6달 변화
-98.84%
년간 변동율
-98.76%
이전 종가
234.6 6
Open
2.3 2
저가
2.3 2
High
2.3 2
양
61
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
  • Market Capitalization 46.49 M
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
30.84
주가매출액비율
14.31
주당 배당금
2.5
배당수익률 %
1.32

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

뉴스